|                        | Hepatitis B Virus (HBV) Fact Sheet   |
|------------------------|--|
|                        | (adapted from materials developed by the Centers for Disease Control and Prevention)   |
| Report to Iowa Dept.   | Acute HAV infection  |
| of Public Health       | Chronic HBV infection  |
|                        | Hepatitis B surface antigen (HBsAg)-positive women of childbearing age   |
| Report to Local Health | HBsAg-positive pregnant women (include vaccination dates, serology dates and test results for infants born   |
| Department             | to HBsAg-positive mothers).  |
| Etiology               | HBV is a DNA-containing virus classified as a hepadnavirus. Important components include HBsAg,  |
| 27                     | hepatitis B core antigen (HBcAg), and hepatitis B e antigen (HBeAg).   |
| Signs and Syptoms      | May be asymptomatic.   |
|                        | Older person are more likely to have symptoms; however, 50% of adults with acute infection are   |
|                        | asymptomatic. Onset of symptoms is insidious and may include fever, tiredness, loss of appetite,   |
|                        | nausea, abdominal discomfort, dark urine, or jaundice.   |
|                        | Average incubation period is 90 days (range: 45-160 days).   |
| Long-Term Effects      | Cirrhosis and hepatocellular carcinoma due to chronic infection. A person is considered to have chronic  |
|                        | HBV infection if HBsAg-positive for 6 months or longer or IgM anti-HBc-negative and HBsAg-positive.  |
|                        | Chronic infection occurs in:   |
|                        | - 90% of infants at birth,   |
|                        | - 30% of children infected at 1-5 years of age,  |
|                        | - 6% of persons infected after 5 years of age.   |
|                        | Death from chronic liver disease occurs in 15-25% of chronically infected persons.   |
| Transmission           | • Transmitted in blood or body fluids (e.g., wound exudates, semen, cervical secretions, or saliva of  |
|                        | HBsAg-positive persons) via:   |
|                        | - unprotected sex with an infected person  |
|                        | <ul> <li>sharing needles or "works" when "shooting" drugs</li> </ul>   |
|                        | - needlesticks or sharps exposure on the job   |
|                        | - sharing personal care items that could be contaminated with blood (e.g., razor, toothbrush)  |
|                        | - infected mother to bay during birth  |
|                        | Blood and serum contain the highest concentrations of virus.  The right of transmission via colling is unknown and not common  |
| Communicability        | <ul> <li>The risk of transmission via saliva is unknown and not common.</li> <li>Anyone who is HBsAg-positive can transmit the virus. Persons with chronic HBV infection are considered</li> </ul> |
| Communicability        | infectious and are the primary reservoirs of infection.  |
|                        | infectious and are the primary reservoirs of infection.  |
| Risk Groups            | Persons with multiple sex partners or sexually     Infants born to HBV-infected mothers  |
|                        | transmitted disease(s) Infants/children born to women from areas with  |
|                        | Men who have sex with men  |
|                        | Sex contacts of infected persons     Health care and public safety workers   |
|                        | Injection drug users     Hemodialysis patients   |
| Prevention             | HBV vaccine us the best protection.  |
|                        | Latex condoms are recommended for sexually active individuals, especially those who have sex with  |
|                        | more than one partner. The efficacy of latex condoms in preventing HBV infection is unknown, but   |
|                        | their proper use may reduce transmission.  |
|                        | <ul> <li>Pregnant women should be tested for HBV. Infants born to HBV-infected mothers should receive HBIG</li> </ul>  |
|                        | (hepatitis B immune globulin) and vaccine within 12 hours of birth.  |
|                        | • Injection drug users should be encouraged: to discontinue injection drug use and to enroll in a  |
|                        | treatment program; to never share needles, syringes, water, or "works," and to receive HAV and HBV   |
|                        | vaccines.  |
|                        | • Do not share personal care items that may be contaminated with blood (e.g., razor, toothbrush).  |
|                        | Persons should be encouraged to consider risks associated with tattoos and body piercings before   |
|                        | receiving either.  |
|                        | Persons who have had HBV infection should not donate blood, organs, or tissue.   |
|                        | Health care or public safety workers should receive HBV vaccine, follow routine barrier precautions,   |
|                        | and handle needles and other sharps safely.  |
| Vaccine                | HBV vaccination for persons 0-18 years of age.   |
| Recommendations        | <ul> <li>Vaccination of high-risk persons of all ages.</li> </ul>  |
|                        |  |
| Medical                | HBV-infected persons should be evaluated for liver disease and received HAV vaccine, if indicated.   |
| Management             | • Alpha interferon and lamivudine are licensed for the treatment of persons with chronic HBV infection;  |
|                        | these drugs are effective in up to 40% of patients. Alpha interferon and lamivudine should not be  |
|                        | used by pregnant women.  |
|                        | Advise against alcohol consumption and, if necessary, provide counseling for alcohol abuse.  |
|                        |  |

| Hepatitis B Virus (HAV) Fact Sheet<br>(adapted from materials developed by the Centers for Disease Control and Prevention) |  |
|--|--|
| Post-Exposure<br>Management  | See Tables on pages 48 and 49  |
| Trends and Statistics  | <ul> <li>Number of new infections per year in the U.S. has declined from an average of 450,000 in the 1980's to approximately 80,000 in 1999.</li> <li>Highest rate of disease occurs in persons 20-49 years of age.</li> <li>Greatest decline in incidence has occurred among children and adolescents, due to routine HBV vaccination.</li> <li>An estimated 1.25 million persons in the U.S. are chronically infected; 20-30% acquired their infectior in childhood.</li> </ul> |